Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Nab-paclitaxel (Abraxane®) in Patients With Relapsed or Refractory Multiple Myeloma

NCT01646762 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT01646762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01646762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Nab-paclitaxel (Abraxane®) in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Terminated
Start date
November 5, 2012
Completion date
October 27, 2015
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory plasma cell myeloma